Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024

SELL
$2.71 - $19.57 $436,852 - $3.15 Million
-161,200 Reduced 80.12%
40,000 $113,000
Q4 2023

Feb 14, 2024

BUY
$12.07 - $18.46 $2.43 Million - $3.71 Million
201,200 New
201,200 $2.96 Million
Q1 2023

May 15, 2023

BUY
$27.71 - $40.93 $96,985 - $143,255
3,500 Added 13.21%
30,000 $880,000
Q4 2022

Feb 14, 2023

SELL
$29.75 - $39.26 $4.31 Million - $5.68 Million
-144,800 Reduced 84.53%
26,500 $979,000
Q3 2022

Nov 14, 2022

BUY
$17.15 - $30.92 $2.4 Million - $4.33 Million
140,000 Added 447.28%
171,300 $4.82 Million

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $237M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.